- Stocks
- Pharma & Healthcare
- Windlas Biotech
Windlas Biotech share price
NSE: WINDLASPharma & HealthcareDrug Manufacturers - Specialty & Generic
Windlas Biotech at a glance
Windlas Biotech (NSE: WINDLAS) closed at ₹885.70 on 22 Oct 2026, down 0.20% on the day. With a market capitalisation of ₹1,828 Cr, it ranks 1180th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 28.4× trailing earnings, against a return on equity of 11.5% in FY26. Over the past year the share price has fallen 2.2%. Its 52-week range is ₹697.40 (16 Mar 2026) to ₹1,181.90 (7 Sep 2026); the last close is 25.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹239 Cr (+17.7% year on year) and net profit ₹16 Cr (−1.8%), on a consolidated basis. Promoters held 63.31% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,828 CrRank 1180 on NSE
- P/E (trailing)
- 28.4×
- Price to book
- 2.68×FY26
- EPS (TTM)
- ₹31.61to Q4 FY26
- ROE
- 11.5%FY26
- ROCE
- 15.7%FY26
- Debt to equity
- 0.05FY26
- Net profit margin
- 7.4%FY26
- Book value / share
- ₹275.20FY26
- Dividend payout
- 18.3%FY26
- 52-week high
- ₹1,181.907 Sep 2026
- 52-week low
- ₹697.4016 Mar 2026
- 1-year return
- −2.2%
- RSI (14-day)
- 26.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.20% | −3.1% | −21.6% | +1.8% | −2.2% |
Windlas Biotech quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹175 Cr | ₹187 Cr | ₹195 Cr | ₹203 Cr | ₹210 Cr | ₹222 Cr | ₹233 Cr | ₹239 Cr |
| Revenue YoY | +21.0% | +22.5% | +20.2% | +18.3% | +19.9% | +18.9% | +19.5% | +17.7% |
| Net profit | ₹13 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹16 Cr |
| Net profit YoY | +11.7% | +11.6% | +3.2% | −4.2% | +31.0% | +13.7% | −3.7% | −1.8% |
| Net margin | 7.7% | 8.4% | 8.0% | 8.0% | 8.4% | 8.0% | 6.4% | 6.7% |
| EPS | ₹6.47 | ₹7.49 | ₹7.45 | ₹7.77 | ₹8.43 | ₹8.48 | ₹7.12 | ₹7.58 |
Windlas Biotech financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹466 Cr | ₹513 Cr | ₹631 Cr | ₹760 Cr | — |
| Operating profit | ₹46 Cr | ₹57 Cr | ₹77 Cr | ₹80 Cr | — |
| Net profit | ₹38 Cr | ₹43 Cr | ₹58 Cr | ₹61 Cr | — |
| EPS (₹) | ₹19.00 | ₹20.00 | ₹28.00 | ₹29.00 | — |
| Cash from operations | ₹9 Cr | ₹61 Cr | ₹109 Cr | ₹68 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹395 Cr | ₹402 Cr | ₹450 Cr | ₹506 Cr | ₹581 Cr |
Windlas Biotech shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 26 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 62.34% | 61.99% | 61.99% | 61.90% | 63.31% | 63.31% |
| Foreign institutions | 1.44% | 1.11% | 0.93% | 0.60% | 0.99% | 2.04% |
| Domestic institutions | 11.21% | 11.43% | 11.44% | 11.81% | 10.20% | 9.84% |
| Non-institutions | 25.01% | 25.47% | 25.64% | 25.70% | 25.50% | 24.80% |
Windlas Biotech vs peers
The listed Pharma & Healthcare companies nearest to Windlas Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BETABeta Drugs | ₹1,773.00 | +5.60% | +3.3% | ₹1,966 Cr | 43.4 | — |
| HESTERBIOHester Biosciences | ₹2,165.00 | −0.37% | +25.4% | ₹1,842 Cr | 32 | — |
| WINDLASWindlas Biotech | ₹885.70 | −0.20% | −2.2% | ₹1,828 Cr | 28.4 | — |
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
| FISCHERFischer Medical Ventures | ₹26.21 | +3.80% | −72.0% | ₹1,715 Cr | 58.2 | — |
| NGLFINENGL Fine-Chem | ₹2,717.20 | +3.00% | +80.2% | ₹1,679 Cr | 34.8 | — |
| KRSNAAKrsnaa Diagnostics | ₹510.75 | −0.79% | −38.5% | ₹1,657 Cr | 16.5 | — |
Ask anything about Windlas Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against WINDLAS's own history. Try: “Why has WINDLAS moved over the last three months?” · “Backtest a 50-day moving-average crossover on WINDLAS over five years” · “Compare WINDLAS with BETA on margins and valuation”
Frequently asked questions about Windlas Biotech
What is the share price of Windlas Biotech today?
Windlas Biotech (NSE: WINDLAS) last closed at ₹885.70 on 22 Oct 2026. Its 52-week high is ₹1,181.90 and its 52-week low is ₹697.40.
What is the market cap of Windlas Biotech?
Windlas Biotech's market capitalisation is ₹1,828 Cr (₹1,828 Cr) at the 22 Oct 2026 close, ranking 1180th among the NSE companies Pivot tracks.
What is the P/E ratio of Windlas Biotech?
Windlas Biotech trades at a trailing P/E of 28.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.8.
What is the ROE and ROCE of Windlas Biotech?
Return on equity was 11.5% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures).
Is Windlas Biotech a debt-free company?
Windlas Biotech is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.
What were Windlas Biotech's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Windlas Biotech reported revenue of ₹239 Cr, +17.7% year on year, and net profit of ₹16 Cr, −1.8% year on year.
How has Windlas Biotech stock performed over the last year?
Windlas Biotech's share price has fallen 2.2% over the past year, +1.8% over three months and −21.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Windlas Biotech?
As of 30 Jun 2026: promoters 63.31%, foreign institutions 2.04%, domestic institutions 9.84%, non-institutions 24.80%.
Who are Windlas Biotech's competitors?
The listed Pharma & Healthcare companies closest to Windlas Biotech by market cap are Beta Drugs, Hester Biosciences, Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem and Krsnaa Diagnostics.
Is Windlas Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Windlas Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WINDLAS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with W · all NSE stocks · this page as text